| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP3K7IP2 |
| Uniprot No | Q9NYJ8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 401-693aa |
| 活性数据 | MRNQPTLFISTNSGASAASRNMSGQVSMGPAFIHHHPPKSRAIGNNSATSPRVVVTQPNTKYTFKITVSPNKPPAVSPGVVSPTFELTNLLNHPDHYVETENIQHLTDPTLAHVDRISETRKLSMGSDDAAYTQALLVHQKARMERLQRELEIQKKKLDKLKSEVNEMENNLTRRRLKRSNSISQIPSLEEMQQLRSCNRQLQIDIDCLTKEIDLFQARGPHFNPSAIHNFYDNIGFVGPVPPKPKDQRSIIKTPKTQDTEDDEGAQWNCTACTFLNHPALIRCEQCEMPRHF |
| 分子量 | 37.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组人MAP3K7IP2（TAB2）蛋白相关的参考文献示例：
---
1. **文献名称**: *"TAK1 regulates NF-κB activation through specific interaction with TAB2"*
**作者**: Cheung PCF et al.
**摘要**: 研究揭示了重组人MAP3K7IP2（TAB2）通过其C端结构域与TAK1激酶结合，介导炎症信号通路中NF-κB的激活机制，为TAB2在先天免疫中的作用提供了实验依据。
---
2. **文献名称**: *"Structural basis for specific recognition of TAK1-binding protein 2 by the E3 ligase ITCH"*
**作者**: Chen Y et al.
**摘要**: 通过X射线晶体学解析了TAB2的PPxY基序与E3泛素连接酶ITCH的WW结构域复合物结构，揭示了TAB2在泛素化修饰中的调控机制及其对细胞凋亡信号的影响。
---
3. **文献名称**: *"TAB2 deficiency induces autophagy in breast cancer cells through AMPK/mTOR pathway"*
**作者**: Li X et al.
**摘要**: 通过构建TAB2敲除的乳腺癌细胞模型，发现TAB2通过调控AMPK/mTOR通路影响自噬水平，其重组蛋白的恢复实验证实了该蛋白在肿瘤代谢中的保护作用。
---
**注**：以上文献为假设性示例，实际研究中建议通过PubMed或Web of Science检索最新论文，关键词为“TAB2 protein”或“MAP3K7IP2 signaling”。
Recombinant human MAP3K7IP2 protein, also known as TGF-β-activated kinase 1 (MAP3K7)-binding protein 2 (TAB2), is a key regulatory component in cellular signaling pathways. It functions as an adaptor protein that links upstream signals to the activation of MAP3K7/TAK1. a kinase critical for mediating NF-κB and MAPK signaling cascades. These pathways are involved in diverse processes, including immune responses, inflammation, apoptosis, and stress responses. TAB2 specifically facilitates TAK1 activation by recruiting it to polyubiquitinated substrates through its C-terminal ubiquitin-binding domain, enabling transduction of signals from cytokines (e.g., TNF-α, IL-1) or pattern recognition receptors (e.g., TLRs).
Recombinant TAB2 is typically produced using engineered expression systems (e.g., *E. coli*, mammalian cells) to ensure proper folding and post-translational modifications. Its production enables detailed *in vitro* studies of TAK1 complex assembly, phosphorylation dynamics, and pathway crosstalk. Researchers utilize recombinant TAB2 to investigate dysregulated signaling in diseases like cancer, autoimmune disorders, and chronic inflammation. Additionally, it serves as a tool for screening small-molecule inhibitors or modulators targeting TAK1-dependent pathways. Structural analyses of TAB2 interactions with TAK1 or ubiquitin chains have also advanced drug design efforts. By providing a controlled, high-purity protein source, recombinant TAB2 significantly contributes to mechanistic and therapeutic studies of intracellular signaling networks.
×
